Top

Rheumatology International

Published in:

01-07-2020 | Secondary Hemophagocytic Lymphohistiocytosis | Correspondence

Cyclosporine therapy in cytokine storm due to coronavirus disease 2019 (COVID-19)

Authors: Erkan Cure, Adem Kucuk, Medine Cumhur Cure

Published in: Rheumatology International | Issue 7/2020

Excerpt

Dear Editor, …

Song J, Kang S, Choi SW, Seo KW, Lee S, So MW, Lim DH (2020) Coronavirus disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs. Rheumatol Int. https://doi.org/10.1007/s00296-020-04584-7 CrossRefPubMedPubMedCentral

Georgiev T (2020) Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs. Rheumatol Int 40:825–826. https://doi.org/10.1007/s00296-020-04570-z CrossRefPubMedPubMedCentral

Chighizola CB, Ong VH, Meroni PL (2017) The use of cyclosporine a in rheumatology: a 2016 comprehensive review. Clin Rev Allergy Immunol 52:401–423. https://doi.org/10.1007/s12016-016-8582-3 CrossRefPubMed

Carbajo-Lozoya J, Ma-Lauer Y, Malešević M et al (2014) Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir. Virus Res 184:44–53. https://doi.org/10.1016/j.virusres.2014.02.010 CrossRefPubMedPubMedCentral

Russell B, Moss C, George G, Santaolalla A et al (2020) Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. Ecancermedicalscience 14:1022. https://doi.org/10.3332/ecancer.2020.1022 CrossRefPubMedPubMedCentral

de Wilde AH, Zevenhoven-Dobbe JC, van der Meer Y et al (2011) Cyclosporin A inhibits the replication of diverse coronaviruses. J Gen Virol 92:2542–2548. https://doi.org/10.1099/vir.0.034983-0 CrossRefPubMedPubMedCentral

Cure E, Cumhur Cure M (2020) Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis. Diabetes Metab Syndr 14:405–406. https://doi.org/10.1016/j.dsx.2020.04.024 CrossRefPubMedPubMedCentral

Dixon DB, Takahashi K, Bieda M, Copenhagen DR (1996) Quinine, intracellular pH and modulation of hemi-gap junctions in catfish horizontal cells. Vis Res 36:3925–3931CrossRefPubMed

Forsse A, Nielsen TH, Nygaard KH, Nordström CH, Gramsbergen JB, Poulsen FR (2019) Cyclosporin A ameliorates cerebral oxidative metabolism and infarct size in the endothelin-1 rat model of transient cerebral ischaemia. Sci Rep 9:3702. https://doi.org/10.1038/s41598-019-40245-x CrossRefPubMedPubMedCentral

10.

Epting T, Hartmann K, Sandqvist A, Nitschke R, Gordjani N (2006) Cyclosporin A stimulates apical Na⁺/H⁺ exchange in LLC-PK1/PKE20 proximal tubular cells. Pediatr Nephrol 21:939–946CrossRefPubMed

11.

Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ (2020) HLH across speciality collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395:1033–1034. https://doi.org/10.1016/S0140-6736(20)30628-0 CrossRefPubMedPubMedCentral

12.

Behrens EM, Koretzky GA (2017) Review: cytokine storm syndrome: looking toward the precision medicine era. Arthritis Rheumatol 69:1135–1143. https://doi.org/10.1002/art.40071 CrossRefPubMed

13.

Elgebaly SA, Elbayoumi T, Kreutzer DL (2017) Cyclosporin H: a novel anti-inflammatory therapy for influenza flu patients. J Egypt Soc Parasitol 47:25–33PubMed

14.

Palau V, Riera M, Soler MJ (2020) ADAM17 inhibition may exert a protective effect on COVID-19. Nephrol Dial Transplant. https://doi.org/10.1093/ndt/gfaa093 CrossRefPubMed

15.

Akool ES, Gauer S, Osman B et al (2012) Cyclosporin A and tacrolimus induce renal Erk1/2 pathway via ROS-induced and metalloproteinase-dependent EGF-receptor signaling. Biochem Pharmacol 83:286–295. https://doi.org/10.1016/j.bcp.2011.11.001 CrossRef

16.

Campana C, Regazzi MB, Buggia I, Molinaro M (1996) Clinically significant drug interactions with cyclosporin. An update. Clin Pharmacokinet 30:141–179CrossRefPubMed

17.

Perico L, Benigni A, Remuzzi G (2020) Should COVID-19 concern nephrologists? Why and to what extent? The emerging impasse of angiotensin blockade. Nephron. https://doi.org/10.1159/000507305 CrossRefPubMed

Title: Cyclosporine therapy in cytokine storm due to coronavirus disease 2019 (COVID-19)
Authors: Erkan Cure
Adem Kucuk
Medine Cumhur Cure
Publication date: 01-07-2020
Publisher: Springer Berlin Heidelberg
Keywords: Secondary Hemophagocytic Lymphohistiocytosis
Severe Acute Respiratory Syndrome Coronavirus
SARS-CoV-2
COVID-19
Cytokines
Published in: Rheumatology International / Issue 7/2020
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-020-04603-7

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Cyclosporine therapy in cytokine storm due to coronavirus disease 2019 (COVID-19)

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 7/2020

Quality of life in children suffering from juvenile idiopathic arthritis-associated uveitis

Disease course and healthcare costs of a cohort of rheumatoid arthritis patients from Turkey

Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis

Longitudinal associations between depressive symptoms and clinical factors in ankylosing spondylitis patients: analysis from an observational cohort

Shoulder ultrasound and serum lactate dehydrogenase predict inadequate response to glucocorticoid treatment in patients with polymyalgia rheumatica

Macrophage activation syndrome in adult dermatomyositis: a case-based review

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page